Redwood AI’s Drug Discovery Pact Fails to Halt Slide as Three-Month Rally Fades

Redwood AI shares fell 17.89% to C$7.80 after a 356% rally, as a partnership with Resilience Biosciences lacked financial details, leaving investors unimpressed.

The announcement of a new collaboration with Resilience Biosciences did little to stem the bleeding at Redwood AI last week. Shares of the Canadian technology company closed at C$7.80 on Friday, down 2.5% on the day and 17.89% lower over the week. The pullback comes on the heels of a staggering 356.14% gain over the past three months — a rally that has recently run out of steam.

The deal with Resilience, made public on May 22, is squarely aimed at accelerating early-stage drug discovery. Redwood AI will deploy its artificial intelligence platform to support the development of small-molecule therapeutics, a process the company claims can slash the decade-long, multi-billion-dollar timeline traditionally required. The platform brings together computational chemistry, cheminformatics, and synthesis route design. Its algorithms systematically generate novel chemical derivatives, assess patentability, and conduct retrosynthetic analyses to determine the most efficient ways to build complex molecules.

A key element of the agreement is the co-development of an assistive workflow that helps scientists modify basic drug scaffolds and explore previously uncharted chemical space. The collaboration targets a pharmaceutical market projected to reach $2.35 trillion globally by 2030. Yet for all the strategic fanfare, the market response was muted. Redwood AI’s press release included no revenue forecasts, milestone payments, or commercialization timeline — leaving investors with little more than a statement of intent.

The absence of hard numbers amplified the technical damage already evident in the stock chart. After hitting C$9.50 on May 15, shares slid to C$7.95 by May 19 — a single-day plunge of 16.32% — before staging a brief recovery to C$8.19. The decline then resumed, taking the stock to C$8.00 and finally to C$7.80 on Friday. Volume on the last trading day was a thin 26,797 shares, well below the 20-day average of 49,372, suggesting the move was driven by a lack of buying interest rather than outright panic.

The technical picture reflects a market in two minds. Redwood AI now trades below both its 5-day moving average of C$8.288 and its 20-day line of C$8.728, while the 50-day moving average at C$6.989 remains comfortably underneath. The short-term trend has clearly turned south, but the medium-term structure is still upright. The relative strength index (RSI) sits at 39.93 on a 9-day basis and 47.92 on a 14-day basis, putting the stock in a neutral zone rather than oversold territory.

Support levels to watch are the weekly low of C$7.00, followed by the monthly low of C$6.20. On the upside, resistance lies at C$8.00, then the two moving averages, and ultimately the recent high of C$9.50. The coming sessions will determine whether buyers step in to reclaim the short-term averages or whether the stock drifts toward the C$7.00 area as the next test.

The Resilience partnership is the latest in a string of platform developments. Earlier this month, Redwood AI expanded its Reactosphere platform with an optimization module that combines Bayesian optimization, design of experiments, and sampling planning for pharmaceutical, materials science, and chemical applications. The strategic direction is clear — artificial intelligence in chemistry and drug discovery — but the market is demanding more concrete evidence of commercial traction before it rewards the stock again.